The DPP-4 inhibitor sitagliptin improves glycaemic control and early-stage diabetic nephropathy in adolescents with type 1 diabetes using the MiniMed 780G advanced hybrid closed-loop system: a randomised controlled trial
Open Access
- 14 September 2024
- journal article
- research article
- Published by Springer Nature in Diabetologia
- Vol. 67 (12) , 2637-2649
Abstract
Aims/hypothesis: Dipeptidyl peptidase-4 (DPP-4) inhibition has beneficial effects on various metabolic indicators in diabetes. Stromal cell-derived factor-1 (SDF-1) is expressed in diverse organs including the kidneys and is cleaved and inactivated by DPP-4 enzyme. The aim of this study was to conduct a randomised controlled trial to assess the effect of sitagliptin on diabetic nephropathy when used as an add-on therapy to the advanced hybrid closed-loop (AHCL) system in adolescents with type 1 diabetes and nephropathy. Methods: This open-label, parallel-group, randomised controlled trial took place at the Pediatric Diabetes Clinic, Ain Shams University, Egypt. Forty-six adolescents aged 14.13 ± 2.43 years on the MiniMed 780G system for at least 6 months before study, with HbA1c ≤69 mmol/mol (8.5%) and diabetic nephropathy in the form of microalbuminuria, were randomly assigned to two groups (n=23 for each) based on a computer-generated randomisation sequence. The intervention group received oral sitagliptin 50 mg for 3 months. The other group used AHCL only and served as a control group. The primary outcome measure was the change in urinary albumin/creatinine ratio (UACR) after 3 months of administration of sitagliptin. The key secondary outcome measure was the change from baseline in SDF-1 levels after treatment. Results: Data for all participants were analysed. No significant difference was found between the groups as regards baseline clinical and laboratory characteristics as well as AHCL system settings (p>0.05). Serum SDF-1 levels were higher in all individuals with type 1 diabetes vs healthy control individuals (ppp<0.001). In addition, sitagliptin reduced postprandial glucose, sensor glucose, coefficient of variation and total daily dose of insulin, while time in range 3.9–10.0 mmol/l (70–180 mg/dl) and insulin-to-carbohydrate ratio were significantly increased. Sitagliptin was safe and well-tolerated without severe hypoglycaemia or diabetic ketoacidosis. Conclusions/interpretation: Sitagliptin as an add-on therapy to AHCL had a reno-protective effect for individuals with type 1 diabetes and diabetic nephropathy, in addition to the improvement of time in range while reducing glycaemic variability and without compromising safety. Funding: This research received no specific grant from any funding agency in the public, commercial or not-for-profit sectors. Trial registration: ClinicalTrials.gov NCT06115460. GraphicalKeywords
Funding Information
- Ain Shams University
This publication has 50 references indexed in Scilit:
- Acute and chronic kidney complications in children with type 1 diabetes mellitusPediatric Nephrology, 2022
- Serum concentration of angiogenic (CXCL1, CXCL12) and angiostasis (CXCL9, CXCL10) CXC chemokines are differentially altered in normal and gestational diabetes mellitus associated pregnanciesJournal of Diabetes & Metabolic Disorders, 2019
- High levels of stromal cell-derived factor-1α predict short-term progression of renal dysfunction in patients with coronary artery diseaseClinical and Experimental Nephrology, 2019
- Urinary albumin excretion with sitagliptin compared to sulfonylurea as add on to metformin in type 2 diabetes patients with albuminuria: A real-world evidence studyJournal of Diabetes and its Complications, 2016
- Plasma stromal cell-derived factor 1α/CXCL12 level predicts long-term adverse cardiovascular outcomes in patients with coronary artery diseaseAtherosclerosis, 2015
- Significance of CXCL12 in Type 2 Diabetes Mellitus and Its Associated ComplicationsInflammation, 2014
- Sitagliptin: A Review of Its Use in Patients with Type 2 Diabetes MellitusDrugs, 2014
- The novel DPP-4 inhibitors linagliptin and BI 14361 reduce infarct size after myocardial ischemia/reperfusion in ratsInternational Journal of Cardiology, 2013
- Increased Circulating Levels of SDF-1 (CXCL12) in Type 2 Diabetic Patients Are Correlated to Disease State but Are Unrelated to Polymorphism of the SDF-1β Gene in the Iranian PopulationInflammation, 2011
- Dual Blockade of the Homeostatic Chemokine CXCL12 and the Proinflammatory Chemokine CCL2 Has Additive Protective Effects on Diabetic Kidney DiseaseThe American Journal of Pathology, 2011